From: Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
 | Early/less severe (e.g., Stage 1) | Moderate (e.g., Stage 2) | Later/more severe (e.g., Stage 3) |
---|---|---|---|
Discontinue all preservative-containing topical medications | a | a | a |
Medical management | |||
 Topical preservative-free drops | a | a | a |
 Topical preservative-free gel drops or ointments | a | a | a |
 Autologous serum drops, human umbilical cord serum, platelet rich plasma | a | a | a |
 Recombinant human nerve growth factor (cenegermin) | b | a | a |
 Prophylactic topical preservative-free antibiotics (excluding aminoglycosides) |  | a | a |
 Matrix metalloproteinases inhibitors | b | a | a |
Non-surgical intervention (i.e., office procedures) | |||
 Corneal therapeutic contact lenses | b | a | b |
 Fresh-frozen self-retained amniotic membrane |  | a | a |
 Punctal occlusion | a | a | a |
 Synthetic (cyanoacrylate) tissue adhesive |  |  | a |
Surgical intervention (i.e., operating room procedures) | |||
 Tarsorrhaphy |  | b | a |
 Amniotic membrane transplant |  | b | a |
 Corneal neurotization |  | b | a |